Total R&D Commitment to Enhance Technology Focused on Promotion of Health
Genetic Engineering Technology
Having introduced genetic engineering technology, Denka Seiken became the first commercial producer in Japan of Norovirus (NV) antibodies, and developed diagnostic tests.
Expertise in immunoassays
Denka Seiken is a pioneer in the development of latex-enhanced turbidimetric immunoassays based on the antigen-antibody reaction. The 1st latex-enhanced turbidimetric immunoassay was released in the 1980’.
Monoclonal Antibody Development
Denka Seiken develops and produces various kinds of monoclonal antibodies in-house for viruses, bacteria and plasma proteins. Such monoclonal antibodies are used for various diagnostic reagents.
Sterile Pharmaceutical Manufacturing
In the development and production of vaccines, sterile pharmaceutical manufacturing technology is needed in order to meet the very strict standards. After more than half a century of developing and producing vaccines, Denka Seiken uses advanced sterile handling technology built on its abundant experience, and produces excellent quality vaccines.
Expertise in Cell Culture
Since its foundation, Denka Seiken has established technologies for the culture of numerous bacteria, viruses, and other microorganisms, as well as tissues. We have made the maximum use of our advanced technologies in the development of vaccines and diagnostic reagents.
Denka Seiken Co., Ltd.
Nihonbashi Mitsui Tower
1-1 Nihonbashi-Muromachi 2-chome,
Chuo-ku, Tokyo 103-8338, JAPAN
February 11, 1950
1,000 million YEN(JP)
Number of Employees:
725 (As of April 1, 2017)
Production, sales and import and export of clinical chemistry, immunochemistry, bacteriological and virological diagnostic reagents and food/environment testing reagent
Fiscal year ends:
Niigata Plant, Kagamida Plant (Gosen-shi, Niigata)
Tokyo, Osaka, Kanetsu
Sapporo, Sendai, Nagoya, Hiroshima, Fukuoka
Denka Seiken UK Limited
Denka Seiken USA Incorporated
Denka Seiken (SHANGHAI) Co.,Ltd.